Rashi PeripheralQ3 FY24

Rashi Peripheral Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: 819.65P/E: 17.1Market Cap: ₹5.4K CrSector: IT - Hardware

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Rashi Peripheral management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Rashi Peripheral management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Rashi Peripheral — get its next earnings analysis in your feed

Margin guidance

No information is provided regarding the same in the latest conference call.

Order book

No information is provided regarding the same in the latest conference call.

How does Rashi Peripheral rank vs peers in IT - Hardware?

Pro feature
ThisRashi Peripheral

How does Rashi Peripheral rank in IT - Hardware?

Compare Rashi Peripheral against every IT - Hardware company (Q3 FY24) on revenue, margins and earnings-call signals.

View IT - Hardware leaderboard →

Others in IT - Hardware this season

  • Esconet (Q1 FY27)

    The order book model is short-term with execution cycles typically 60-90 days; order book size is around ₹20-25 crores as of June 30. Key concall takeaways…

  • Esconet (Q4 FY25)

    Previous fundraising through preferential allotments (approximately 33 crores last year and 32.69 crores recently) has strengthened financials. Key concall…

  • DC Infotech & Communication Ltd (Q4 FY26)

    . Key concall takeaways from DC Infotech & Communication Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.

  • Control Print Ltd (Q1 FY27)

    Track & Trace market could expand significantly if government mandates extend from top 300 to top 1,000 pharmaceutical brands, growing from ~₹600 crores to…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →